Microbot Medical Secures Third Patent for the LIBERTY® Robotic System in the United States; Success of Protecting Novel Intellectual Property Complements Recent Design Freeze Achievement

Rhea-AI Summary

Microbot Medical (Nasdaq: MBOT) announced the issuance of a Notice of Allowance for a third patent related to its LIBERTY® Robotic System by the USPTO. In 2021, the company secured three U.S. patents, bringing its total to 47 patents issued or allowed worldwide, with an additional 26 pending applications. CEO Harel Gadot stated that this year has been crucial for the LIBERTY system, highlighting the ongoing progress in IP and R&D. The granted claims protect a compact robotic device for surgical tool manipulation, reinforcing the company’s confidence in achieving its clinical goals for 2022.

Positive

• Secured a third patent for the LIBERTY Robotic System, contributing to a total of 47 patents worldwide.
• Demonstrated significant progress in intellectual property and research & development, enhancing the company's competitive position.
• CEO expresses positive outlook for future clinical and operational achievements in 2022.

Negative

• None.

HINGHAM, Mass., Dec. 23, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a third patent application covering the Company’s LIBERTY^® Robotic System. The Company has secured all three U.S. patents during 2021. Globally, the Company now has 47 patents issued/allowed and 26 pending patent applications and is continuously submitting applications to protect its Intellectual Property.

“2021 has been an extremely successful year for our LIBERTY Robotic System – key patents and development progress leading to the recently announced design freeze – so we remain bullish on our future prospects and maintaining the positive momentum,” commented Harel Gadot, CEO, President and Chairman. “The IP and R&D teams are accomplishing meaningful milestones, which gives us greater confidence that we will continue to perform at a high level and execute the clinical and operating objectives we have planned throughout 2022.”

The allowed claims provide protection for embodiments of LIBERTY as a compact robotic device for driving movement of two or more elongate surgical tools, the device having motors and tool actuation assemblies encased within the same device housing.

About Microbot Medical

Microbot Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies, focused primarily on both natural and artificial lumens within the human body. Microbot’s current proprietary technological platforms provide the foundation for the development of a Multi Generation Pipeline Portfolio (MGPP).

Microbot Medical was founded in 2010 by Harel Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of improving clinical outcomes for patients and increasing accessibility through the use of micro-robotic technologies. Further information about Microbot Medical is available at http://www.microbotmedical.com.

Safe Harbor

Statements pertaining to the registered direct offering, timing, the amount and anticipated use of proceeds and statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects” and “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions and the satisfaction of customary closing conditions, risks inherent in the development and/or commercialization of potential products, including LIBERTY and SCS, the outcome of its studies to evaluate LIBERTY, SCS and other existing and future technologies, uncertainty in the results of pre-clinical and clinical trials or regulatory pathways and regulatory approvals, uncertainty resulting from the COVID-19 pandemic, need and ability to obtain future capital, and protection and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Investor Contact:

Michael Polyviou
EVC Group
mpolyviou@evcgroup.com
732-933-2754

 

FAQ

What recent patent did Microbot Medical receive for MBOT?

Microbot Medical received a Notice of Allowance for a third patent related to its LIBERTY® Robotic System.

How many patents does Microbot Medical hold as of 2021?

As of 2021, Microbot Medical has 47 patents issued or allowed worldwide and 26 pending applications.

What does the newly allowed patent protect for the LIBERTY system?

The patent provides protection for a compact robotic device for driving movement of surgical tools.

What was the CEO's comment on Microbot Medical's performance in 2021?

CEO Harel Gadot stated that 2021 was an extremely successful year for the LIBERTY Robotic System, with ongoing positive momentum.

What are the future plans for Microbot Medical following the patent issuance?

Microbot Medical plans to continue executing its clinical and operational objectives throughout 2022.